HK Stock Market Move | SIMCERE PHARMA (02096) rose over 4%. In the US, the first patient enrolled in the Phase I clinical trial of the new ADC candidate drug SIM0505 by Simcere Pharma, is Cleared for Entry.

SIMCERE PHARMA (02096) rose by more than 4%, as of the time of reporting, it was up 3.47% to HKD 13.42, with a turnover of HKD 89.9923 million. On the news front, according to the official WeChat account of SIMCERE PHARMA, on October 16, the anti-tumor innovative drug company under SIMCERE PHARMA, SinoMab BioScience Limited, announced a Phase I clinical trial (NCT06792552) in the United States for SIM0505 for advanced solid tumor patients. The study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the drug. SIM0505 is a novel ADC targeting CDH6 (cadherin-6 or K-cadherin) developed by SinoMab BioScience Limited. Its unique binding site has a higher affinity for tumor antigens compared to similar candidate drugs. SIM0505 also utilizes SinoMab BioScience Limited's proprietary TOPOisomerase 1 inhibitor (TOPOi) as an effective payload, with strong anti-tumor activity and a high clearance rate for broadening the therapeutic window. After the Phase I dose escalation study was initiated in China, it was expanded to the United States by NextCure, with American patients being enrolled in the medium dose group. The study will continue to progress in both China and the United States. NextCure has obtained exclusive global license rights for SIM0505 from SinoMab BioScience Limited in areas outside of Greater China.